Elite Pharmaceuticals ELTP
OTC ELTP
$0.37 +0.05 (+15.63%)
At close: Nov 16, 2026 · 4:00 PM EST

Elite Pharmaceuticals (ELTP) Net Income towards Common Stockholders (2009 - 2026)

Updated

Elite Pharmaceuticals (ELTP) posted Net Income towards Common Stockholders of $17.32 million for fiscal Q2 2027 (quarter ended Sep 30, 2026), up 26.4% from $13.7 million a year earlier and up 193.0% from the prior quarter.

Analysis

Elite Pharmaceuticals (ELTP) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends

For the trailing twelve months through Sep 30, 2026, Net Income towards Common Stockholders at Elite Pharmaceuticals was $60.28 million, up 333.0% year-over-year; for FY2026 (ended Mar 31, 2026), it was $44.87 million.

  • Annual Net Income towards Common Stockholders shows a five-year compound annual growth rate of 54.6% (FY2021 to FY2026).
  • In prior fiscal years, Elite Pharmaceuticals' Net Income towards Common Stockholders was -$4.31 million in FY2025, $20.11 million in FY2024 (+464.6%), $3.56 million in FY2023 (-60.0%) and $8.9 million in FY2022 (+74.9%).
  • Quarterly Net Income towards Common Stockholders has run from a low of -$11.04 million in fiscal Q2 2025 to a high of $18.59 million in fiscal Q3 2026 over five years.
  • The strongest year-over-year quarter for Net Income towards Common Stockholders in the past five years was fiscal Q2 2024, with growth of 577.8%; the weakest was fiscal Q1 2023, with a decline of 87.2%.
  • According to Business Quant data, Net Income towards Common Stockholders for the three prior fiscal quarters was $5.91 million (Q1 2027), $18.46 million (Q4 2026) and $18.59 million (Q3 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn 6.45 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 210.00 Mn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn 4.22 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 5.07 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn 3.12 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn 3.86 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn 2.43 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 3.24 Bn
10 Elite Pharmaceuticals 401.23 Mn 274.64 Mn 15.99 Mn 17.32 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 17.32 Mn
Jun 30, 2026 5.91 Mn
Mar 31, 2026 18.46 Mn
Dec 31, 2025 18.59 Mn
Sep 30, 2025 13.70 Mn
Jun 30, 2025 -5.88 Mn
Mar 31, 2025 17.00 Mn
Dec 31, 2024 -10.89 Mn
Sep 30, 2024 -11.04 Mn
Jun 30, 2024 615,773.00
Mar 31, 2024 3.33 Mn
Dec 31, 2023 706,354.00
Sep 30, 2023 14.93 Mn
Jun 30, 2023 1.14 Mn
Mar 31, 2023 -1.79 Mn
Dec 31, 2022 3.34 Mn
Sep 30, 2022 2.20 Mn
Jun 30, 2022 305,883.00
Mar 31, 2022 2.43 Mn
Dec 31, 2021 2.28 Mn
API Access

Elite Pharmaceuticals Net Income towards Common Stockholders API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=ELTP&period=max&api_key=YOUR_API_KEY